Biodesix Inc. Files S-1/A Amendment

TL;DR

Biodesix filed an S-1/A. Looks like ongoing SEC stuff.

AI Summary

Biodesix, Inc. filed an S-1/A amendment on May 24, 2024, for its registration statement. The company, headquartered in Boulder, Colorado, is involved in medical laboratories (SIC code 8071). Scott Hutton is the President and CEO. The filing relates to the Securities Act of 1933.

Why It Matters

This S-1/A filing indicates ongoing regulatory activity for Biodesix, Inc., potentially related to securities offerings or compliance updates.

Risk Assessment

Risk Level: low — This is a routine S-1/A filing, which is an amendment to a registration statement, not a direct indication of immediate financial distress or high risk.

Key Numbers

• 333-278881 — SEC File Number (Identifies the specific registration filing with the SEC.)
• 8071 — SIC Code (Indicates the company operates in the Medical Laboratories industry.)

Key Players & Entities

• BIODESIX INC (company) — Registrant
• May 24, 2024 (date) — Filing date
• Scott Hutton (person) — President and Chief Executive Officer
• 333-278881 (registration_number) — SEC Registration Number
• 8071 (sic_code) — Standard Industrial Classification Code for Medical Laboratories

FAQ

Key Financial Figures

• $0.001 — Convertible Preferred Stock, par value $0.001 (the Series A Preferred Stock). Subject
• $1.41 — rted sale price of our Common Stock was $1.41. We are an emerging growth company an
• $1.24 billion — fiscal year in which we have more than $1.24 billion in annual revenue; (ii) the date we qua
• $700 million — large accelerated filer, with at least $700 million of equity securities held by non-affili
• $1.0 billion — ed, in any three-year period, more than $1.0 billion in non-convertible debt securities; and
• $250 million — on Stock held by non-affiliates exceeds $250 million as of the end of that years second fisc
• $100 million — r, or (ii) our annual revenues exceeded $100 million during such completed fiscal year and t

Filing Documents

• d827839ds1a.htm (S-1/A) — 1351KB
• d827839dex51.htm (EX-5.1) — 8KB
• d827839dex231.htm (EX-23.1) — 1KB
• g827839g39e87.jpg (GRAPHIC) — 105KB
• g827839g39f89.jpg (GRAPHIC) — 97KB
• g827839g39g90.jpg (GRAPHIC) — 88KB
• g827839g39h91.jpg (GRAPHIC) — 139KB
• g827839g57a04.jpg (GRAPHIC) — 3KB
• g827839g78y82.jpg (GRAPHIC) — 98KB
• g827839g78z86.jpg (GRAPHIC) — 82KB
• g827839g82q02.jpg (GRAPHIC) — 63KB
• 0001193125-24-147047.txt ( ) — 2264KB

USE OF PROCEEDS

USE OF PROCEEDS 67

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 68 CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE 86

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 87

BUSINESS

BUSINESS 88 MANAGEMENT 129

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 134

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 142 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 145 SELLING STOCKHOLDERS 147 PLAN OF DISTRIBUTION 153

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 156 LEGAL MATTERS 162 EXPERTS 163 WHERE YOU CAN FIND MORE INFORMATION 164 INCORPORATION OF CERTAIN INFORMATION BY REFERENCE 165 INFORMATION NOT REQUIRED IN PROSPECTUS II-1 i Table of Contents ABOUT THIS PROSPECTUS This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission, (the SEC), using a shelf registration process. Under this shelf registration process, the Selling Stockholders may, from time to time, sell the securities described in this prospectus in one or more offerings. Each time we or the Selling Stockholders offer securities, we will provide a prospectus supplement that describes the terms of the relevant offering. The prospectus supplement also may add, update or change information contained in this prospectus. Before making an investment decision, you should read carefully both this prospectus and any prospectus supplement together with the documents incorporated by reference into this prospectus as described below under the heading Incorporation of Certain Information by Reference. We and the Selling Stockholders have not authorized anyone to provide you with different information or to make any representation other than those contained in this prospectus. You should not assume that the information in this prospectus or any supplement to this prospectus is accurate at any date other than the date indicated on the cover page of these documents or the filing date of any document incorporated by reference, regardless of its time of delivery. The Selling Stockholders are not offering to sell, or seeking offers to buy, the securities in any jurisdiction where the offer or sale is not permitted. The Selling Stockholders may sell the Resale Shares on any national securities exchange or quotation service on which the securities may be listed or quoted at the time of sale, in the over-the-counter market, in one or more transactions otherwise than

financial statements with other public companies difficult or impossible

financial statements with other public companies difficult or impossible. Corporate Information We were incorporated in Delaware in 2005 as Elston Technologies, Inc. Our principal executive offices are located at 919 West Dillon Rd., Louisville, Colorado 80027, and our telephone number is (303) 417-0500. On June 20, 2006, we changed our name to Biodesix, Inc. Our website address is www.biodesix.com. Information contained on, or accessible from, or hyperlinked to, our website is not incorporated by reference into this prospectus, and you should not consider information on our website to be part of this prospectus, or in deciding whether to purchase our Common Stock. Our filings with the SEC are posted on our website at www.biodesix.com. Other than the specifically incorporated SEC filings, the information found on or accessible through our website is not part of this prospectus or any other report we file with or furnish to the SEC. The public can also obtain copies of these filings by accessing the SECs website at http://www.sec.gov. Recent Development

View Full Filing

View this S-1/A filing on SEC EDGAR